Recent Updates
Recently added Catalysts

Standard of Care

Phase 1

Surgical Wound Infection | Small molecule | Infectious Disease |Novo Nordisk A/S|Last Updated: May 6, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Clinical trial landscape

Standard of Care · 1 trial · 2 indications

Phase 1 1
NCT07379684A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound InfectionsSurgical Wound Infection
RECRUITING44 Analytics
PHASE1RECRUITING
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
Surgical Wound InfectionUnlock trial analytics

Study Endpoints

Primary Endpoints

Overall comparison of treatment emergent adverse events (TEAES) of combined SOC + Amicidin-β topical solution recipients to SOC only recipients across 3 cohorts.
From Day 1 to Day 30

Secondary Endpoints

Number of participants with Treatment Emergent Adverse Events (TEAEs) by severity according to the study protocol.
From Day 1 to Day 30
Measurement of systemic absorption of Amicidin-β recipients.
From Day 1 to Day 3
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SOC + Amicidin-β topical solution - 15 mLEXPERIMENTALIn addition to Standard of Care (SOC), patients will receive Amicidin-β topical solution - 15 mL immediately prior to wound closure/dressing, with rinsing out with saline.
SOC + Amicidin-β topical solution - 50 mL - Scheme 1EXPERIMENTALIn addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, with rinsing out with saline
SOC + Amicidin-β topical solution - 50 mL - Scheme 2EXPERIMENTALIn addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, without rinsing out with saline
SOCACTIVE_COMPARATORPatients will receive Standard of Care (SOC) only

Interventions

NameTypeDescription
Amicidin-β topical solution - 15 mLDRUGAmicidin-β topical solution for local administration - 15 mL
Amicidin-β topical solution - 50 mLDRUGAmicidin-β topical solution for local administration - 50 mL
Standard of Care (SOC)DRUGPer institutional Standard Of Care
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 79 Years
SexALL
Healthy VolunteersNo
Study Sites4

Main Inclusion Criteria: * Body Mass Index between 18.5 kg/square meter and 39.9kg/square meter * Surgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of th...

Countries:United States
Unlock Eligibility Criteria